研報掘金丨光大證券:維持瀾起科技“買入”評級,看好公司的長期成長空間
光大證券研報指出,DDR5持續滲透且子代持續迭代,瀾起科技鞏固行業領先地位。2024年,公司DDR5內存接口芯片出貨量超過DDR4內存接口芯片。在DDR5內部子代迭代進程中,公司DDR5第二子代RCD芯片2024年出貨量已超過第一子代產品,第三子代RCD芯片於第四季度開始規模出貨;同時,第五子代RCD芯片已順利向客戶送樣。憑藉卓越的技術實力以及產品出色的穩定性和可靠性,公司精準把握DDR5 迭代升級的產業機遇,進一步鞏固行業領先優勢。隨着DDR5的持續滲透,以及公司高速互連芯片持續成長,有望帶動公司淨利潤持續快速增長。看好公司的長期成長空間,維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.